Hjem › Tripelnegativ brystkræft › Oregon
Tripelnegativ brystkræft kliniske forsøg i Oregon
12 studier for Tripelnegativ brystkræft søger deltagere på steder i Oregon.
Byer i Oregon
Officiel studietekst (engelsk)
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Oregon Health & Science University (OHSU), Portland
RekruttererFase 1/2
Alder 12 og opefter · Alle køn · Opdateret 2. okt. 2026 · NCT04585750Study of AVZO-021 in Patients With Advanced Solid Tumors
- Avenzo Therapeutics Recruiting Site, Portland
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 28. sep. 2026 · NCT05867251A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Northwest Cancer Specialists (Compass Oncology) ( Site 8010), Tigard
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT06966700Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
- Providence Portland Medical Center ( Site 0116), Portland
- Providence Oncology and Hematology Care Clinic - Westside ( Site 0126), Portland
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT06393374A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
- Providence Portland Medical Center, Portland
- Providence St. Vincent Medical Center, Portland
- Local Institution - 0052, Portland
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 23. sep. 2026 · NCT06618287Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients
- Providence Portland Cancer Institute - Franz Clinic, Portland
- Providence St. Vincent Medical Center, Portland
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 16. sep. 2026 · NCT06353997Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
- St. Charles Health System, Inc. DBA St. Charles Medical Center, Bend
- Samaritan Hospital, Corvallis
- Willamette Valley Cancer Institute and Research Center, Eugene
- og 1 flere
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 9. sep. 2026 · NCT05633654A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
- Providence Cancer Center Oncology and Hematology Care- Eastside, Portland
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 17. aug. 2026 · NCT04895709A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
- Willamette Valley Cancer Institute, Eugene
RekruttererFase 2/3
Alder 18 og opefter · Alle køn · Opdateret 10. aug. 2026 · NCT06926868Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- USOR Oncology Associates of Oregon, P.C., Eugene
- Compass Oncology - Rose Quarter, Portland
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 4. aug. 2026 · NCT05579366I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
- Oregon Health & Science Institute (OHSU), Portland
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 6. maj 2026 · NCT01042379CtDNA Based MRD Testing for NAC Monitoring in TNBC
- Oregon Oncology Specialists, Salem
RekruttererObservationsstudie
Alder 18 og opefter · Kvinder · Opdateret 7. jan. 2025 · NCT06230185Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.